PPT-A better clinical pathway for cancer monitoring

Antonius Schuh PhD Chief Executive Officer September 2013 ForwardLooking Statements Statements in this presentation about the Companys expectations applications of its technology markets launch of tests and other statements that are not historical facts are forwardlooking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on managements current beliefs assumptions estimates and projections Actual results may differ materially from those projected in the forwardlooking statements for various reasons including risks associated with product and test development test transfer to contracting labs government regulation market acceptance limited commercial experience dependence on key personnel obtaining financing and other factors discussed in the Companys periodic reports filed with the Securities and Exchange Commission. . Presentation. July 2015. OTCQX: RESX. This presentation includes "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our anticipated future clinical and regulatory events, future financial/position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements can be identified by words such as “potential,” "may," "will," "should," "forecast,“ "project," "could," "expect," "believe," "estimate," "anticipate," "intend," "plan,“ “continue”, other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements in this presentation include, without limitation, statements regarding our current business strategies, the potential future commercialization of our product candidates, potential estimated market sizes for our product candidates, anticipated start dates, durations and completion dates, as well as potential future results, of our future clinical trials, anticipated designs of our future clinical trials, and anticipated future regulatory submissions and events. Uncertainties and risks may cause actual results to be materially different than those expressed in or implied by our forward-looking statements. Particular uncertainties and risks include, among others, uncertainties regarding our ability to license out our existing and license in additional products and technologies and the terms of such licenses; uncertainties involved in clinical testing, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent annual report on Form 10-K/A, subsequent quarterly reports on Form 10-Q and final prospectus dated July 31, 2014. All forward-looking statements in this presentation speak only as of the date of this presentation and we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.. Analysis. Charles . J Ryan, MD. Professor of Clinical . Medicine and Urology. Helen Diller Family Comprehensive Cancer Center. University of California, San Francisco. Biomarker Analysis in Prostate . Stirling Bryan, PhD. Graham Scotland, PhD. Mohsen Sadatsafavi, . PhD. Overview of session. Stirling Bryan:. In Search of Efficiency, Consistency, Fairness, and Impact in . HTA. Graham Scotland. Modelling screening and treatment pathways for diabetic retinopathy. Office of Human Subjects Research Institutional Review Board (IRB) Open House. Frederick W. Luthardt, DBE, MA. Manager, OHSR Compliance Monitoring Program. Suzanna Roettger, MA. Senior Compliance Monitoring Specialist. Mr Michael Thomas, Colorectal Cancer SSG, 27. th. June 2018. Audience:. Cancer . Alliances: should work with commissioners and providers to ensure the whole pathway for colorectal cancer is provided within their geographical . November 2021. Aditya Manjunath. Consultant Urological Surgeon. North Bristol NHS Trust . Updates. Demographics. Unchanged – Referrals from SWAG, Three Counties and Peninsula networks. Population – approximately 5 million people . NB. Basal Cell Carcinoma is excluded from the 2 week cancer pathway. Skin . Cancer Pathway . [Final] . Holistic assessment and rehabilitation consideration. 2ww referral received in secondary care. SWAGGER. . Sophia Julian. Consultant Gynaecological Oncologist. sophia.julian@nhs.net. Acknowledgements. Ryan Hogan (post CCT Clinical Fellow). Diagnosing/Excluding Cancer. In first 12 months after menopause 1:10 women report PMB. Sylvia . O’Neill, . MD . Executive Director . . Clinical Research Organization . Teresa . Cardoso, . MS,BSN,RN. . Clinical . Trial Nurse . Educator. Clinical . welcomes you to our inaugural. . MS Teams LIVE Event:. Rapid Diagnostic Services. 08.09.2020. Introduction. Dr Amelia Randle, Clinical Director, SWAG Cancer Alliance. Timetable:. PCN. RDC. RDC. HUB. On behalf of SWAG Alliance. 1. Living . With & Beyond . Cancer (Personalised Care): . SWAG Colorectal CAG Update. By 2021, where appropriate every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan and health and wellbeing information and support. . with. Amelia Randle, SWAG Clinical Director, and. Louise Hunt, Consultant Colorectal Surgeon, . Somerset Foundation Trust . 17.09.2020. Agenda. Agenda Item. Welcome and Introduction. Dr Amelia Randle, Clinical Director, SWAG Cancer Alliance. Use of guidelines. The diagnosis, staging and fitness assessments in this pathway should be completed with reference to current national guidelines. The NOLCP is also supported by a series of . Diagnostic Standards of Care. -gastric . p. athway. Mr. Dip Mukherjee OG Surgeon. National cancer vanguard pathway development member. Pathway director NCELA . WHY ?. The old world . The old world . What ?. 62 day Rule Rules .